Akero Therapeutics rises on up to $5.2 billion buyout deal from Novo

Akero Therapeutics

09/10/2025 14:54

Updates

** Shares of drug developer Akero Therapeutics AKRO.O rise 16.8% to $54.36 in morning trading

** Novo Nordisk NOVOb.CO says it will buy AKRO for $4.7 billion in cash, and $500 million contingent upon meeting certain milestones

** U.S.-listed shares of Danish drugmaker Novo Nordisk NVO.N marginally down

** AKRO is developing a drug for fatty liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which affects more than 5% of the U.S. population

** Including session's move, AKRO shares nearly double YTD

(Reporting by Puyaan Singh and Padmanabhan Ananthan)

((Puyaan.Singh@thomsonreuters.com;))